Equities Analysts Issue Forecasts for ABEO Q1 Earnings

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Abeona Therapeutics Inc. (NASDAQ:ABEO - Free Report) - Analysts at HC Wainwright cut their Q1 2026 earnings per share (EPS) estimates for Abeona Therapeutics in a research note issued on Monday, August 18th. HC Wainwright analyst R. Selvaraju now forecasts that the biopharmaceutical company will post earnings of $0.04 per share for the quarter, down from their prior forecast of $0.05. HC Wainwright currently has a "Buy" rating and a $20.00 price target on the stock. The consensus estimate for Abeona Therapeutics' current full-year earnings is ($1.16) per share.

Abeona Therapeutics (NASDAQ:ABEO - Get Free Report) last issued its earnings results on Thursday, August 14th. The biopharmaceutical company reported $1.71 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.39) by $2.10. The company had revenue of $0.40 million for the quarter, compared to the consensus estimate of $21.71 million.

A number of other equities research analysts have also commented on ABEO. Oppenheimer raised their price target on Abeona Therapeutics from $19.00 to $20.00 and gave the stock an "outperform" rating in a research report on Friday, August 15th. Wall Street Zen downgraded shares of Abeona Therapeutics from a "hold" rating to a "sell" rating in a report on Thursday, May 15th. Alliance Global Partners reiterated a "buy" rating on shares of Abeona Therapeutics in a report on Thursday, May 15th. Finally, Stifel Nicolaus dropped their price objective on shares of Abeona Therapeutics from $21.00 to $20.00 and set a "buy" rating on the stock in a report on Friday, May 16th. Five research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus target price of $19.50.

Abeona Therapeutics Trading Up 1.7%

Shares of ABEO traded up $0.12 during trading hours on Tuesday, reaching $7.23. The stock had a trading volume of 850,820 shares, compared to its average volume of 710,270. The company has a market cap of $370.75 million, a P/E ratio of 10.33 and a beta of 1.55. Abeona Therapeutics has a 52 week low of $3.93 and a 52 week high of $7.54. The company has a quick ratio of 4.90, a current ratio of 6.73 and a debt-to-equity ratio of 0.09. The firm has a 50-day moving average of $6.30 and a 200 day moving average of $5.79.

Institutional Trading of Abeona Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. Ameritas Investment Partners Inc. bought a new stake in Abeona Therapeutics in the 2nd quarter valued at $25,000. Legal & General Group Plc bought a new stake in Abeona Therapeutics in the 2nd quarter valued at $27,000. Twinbeech Capital LP bought a new stake in Abeona Therapeutics in the 4th quarter valued at $58,000. Riverwater Partners LLC bought a new position in shares of Abeona Therapeutics during the second quarter worth approximately $62,000. Finally, Police & Firemen s Retirement System of New Jersey bought a new position in shares of Abeona Therapeutics during the second quarter worth approximately $63,000. 80.56% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Abeona Therapeutics

In other news, CFO Joseph Walter Vazzano sold 25,411 shares of the firm's stock in a transaction dated Wednesday, July 9th. The shares were sold at an average price of $5.86, for a total transaction of $148,908.46. Following the completion of the sale, the chief financial officer owned 479,168 shares in the company, valued at approximately $2,807,924.48. This trade represents a 5.04% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Vishwas Seshadri sold 69,420 shares of the firm's stock in a transaction dated Wednesday, July 9th. The stock was sold at an average price of $5.86, for a total transaction of $406,801.20. Following the sale, the chief executive officer owned 1,234,341 shares of the company's stock, valued at approximately $7,233,238.26. This represents a 5.32% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 231,626 shares of company stock valued at $1,430,587 in the last three months. Corporate insiders own 6.90% of the company's stock.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.